Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Modine Manufacturing Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Modine Manufacturing Company trades at $241.73 (market cap $12.99B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.1× Modine Manufacturing Company's market cap, and Modine Manufacturing Company is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | MOD | |
|---|---|---|
Market Cap | $39.89B | $12.99B |
Sector | Health | Technology |
52-Week High | $491.22 | $306.89 |
52-Week Low | $278.09 | $90.02 |
Enterprise Value | $38.15B | $13.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Modine (MOD) trades at $245.91, up 0.99% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $2.58 billion in 2025, though net income margin compressed to 3.82%. Analyst consensus remains bullish with a $328.80 price target, supported by 10 buy ratings. Recent news highlights Modine's positioning in the AI data center cooling market, with sales projected to grow 60-80% in fiscal 2027.
The outlook is mixed: robust growth in data center demand offers upside, but high valuation multiples (P/E 108.81) and margin pressures pose risks. Investors face volatility from supply chain challenges and competitive threats in the HVAC segment. Wall Street optimism contrasts with technical weakness, suggesting cautious optimism for long-term growth despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
